CN120827545A - 用于对映体富集的或纯的安非他酮的剂型和方法 - Google Patents

用于对映体富集的或纯的安非他酮的剂型和方法

Info

Publication number
CN120827545A
CN120827545A CN202510967625.3A CN202510967625A CN120827545A CN 120827545 A CN120827545 A CN 120827545A CN 202510967625 A CN202510967625 A CN 202510967625A CN 120827545 A CN120827545 A CN 120827545A
Authority
CN
China
Prior art keywords
bupropion
dosage form
dextromethorphan
human
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202510967625.3A
Other languages
English (en)
Chinese (zh)
Inventor
赫里奥特·塔布提奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antecip Bioventures II LLC
Original Assignee
Antecip Bioventures II LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antecip Bioventures II LLC filed Critical Antecip Bioventures II LLC
Publication of CN120827545A publication Critical patent/CN120827545A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202510967625.3A 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法 Pending CN120827545A (zh)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201862634718P 2018-02-23 2018-02-23
US62/634,718 2018-02-23
US201962794469P 2019-01-18 2019-01-18
US62/794,469 2019-01-18
US201962809480P 2019-02-22 2019-02-22
US62/809,480 2019-02-22
CN201980026874.5A CN112087999A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法
PCT/US2019/019445 WO2019165379A1 (en) 2018-02-23 2019-02-25 Dosage forms and methods for enantiomerically enriched or pure bupropion

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201980026874.5A Division CN112087999A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法

Publications (1)

Publication Number Publication Date
CN120827545A true CN120827545A (zh) 2025-10-24

Family

ID=67688503

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202510967625.3A Pending CN120827545A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法
CN201980026874.5A Pending CN112087999A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201980026874.5A Pending CN112087999A (zh) 2018-02-23 2019-02-25 用于对映体富集的或纯的安非他酮的剂型和方法

Country Status (19)

Country Link
EP (1) EP3755312A4 (https=)
JP (3) JP2021513998A (https=)
KR (3) KR20240091043A (https=)
CN (2) CN120827545A (https=)
AU (3) AU2019223187B2 (https=)
BR (1) BR112020017179A2 (https=)
CA (1) CA3092076A1 (https=)
CL (1) CL2020002166A1 (https=)
CR (1) CR20200415A (https=)
EC (1) ECSP20060179A (https=)
IL (2) IL276871B2 (https=)
MA (1) MA51914A (https=)
MX (2) MX2020008704A (https=)
MY (1) MY202993A (https=)
NI (1) NI202000056A (https=)
NZ (1) NZ767378A (https=)
PE (1) PE20211752A1 (https=)
SG (1) SG11202008056SA (https=)
WO (1) WO2019165379A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL276871B2 (en) * 2018-02-23 2024-11-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660274B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11291639B2 (en) 2018-09-20 2022-04-05 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US11660273B2 (en) 2018-09-20 2023-05-30 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
WO2021055124A1 (en) * 2019-09-20 2021-03-25 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
US20250073188A1 (en) 2020-06-05 2025-03-06 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions
US11717518B1 (en) 2022-06-30 2023-08-08 Antecip Bioventures Ii Llc Bupropion dosage forms with reduced food and alcohol dosing effects
US12156914B2 (en) * 2022-06-30 2024-12-03 Axsome Therapeutics, Inc. Pharmaceutical compositions comprising bupropion and cysteine
US12036191B1 (en) 2022-06-30 2024-07-16 Antecip Bioventures Ii Llc Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
US11730706B1 (en) 2022-07-07 2023-08-22 Antecip Bioventures Ii Llc Treatment of depression in certain patient populations
WO2025259728A1 (en) * 2024-06-13 2025-12-18 Antecip Bioventures Ii Llc Compounds and combinations thereof for treating neurological and psychiatric conditions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1051166A1 (en) * 1998-01-29 2000-11-15 Sepracor, Inc. Pharmaceutical uses of optically pure (+) -bupropion
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
WO2005016318A1 (en) * 2003-08-08 2005-02-24 Biovail Laboratories Inc. Modified-release tablet of bupropion hydrochloride
WO2012118562A1 (en) * 2011-03-02 2012-09-07 Rhine Pharmaceuticals, Llc Compositions and methods for treating depression, adhd and other central nervous system disorders employing novel bupropion compounds, and methods for production and use of novel bupropion compounds and formulations
US10080727B2 (en) * 2013-11-05 2018-09-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
US9198905B2 (en) * 2013-11-05 2015-12-01 Antecip Bioventures Ii Llc Compositions and methods for reducing dextrorphan plasma levels and related pharmacodynamic effects
US9474731B1 (en) * 2013-11-05 2016-10-25 Antecip Bioventures Ii Llc Compositions and methods for increasing the metabolic lifetime of dextromethorphan and related pharmacodynamic effects
WO2015095713A1 (en) * 2013-12-20 2015-06-25 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
IL276871B2 (en) * 2018-02-23 2024-11-01 Axsome Therapeutics Inc Dosage forms and methods for enantiomerically enriched or pure bupropion

Also Published As

Publication number Publication date
KR20210003091A (ko) 2021-01-11
IL276871B1 (en) 2024-07-01
CR20200415A (es) 2021-02-03
IL276871B2 (en) 2024-11-01
AU2019223187B2 (en) 2022-07-28
CL2020002166A1 (es) 2020-10-23
JP2022153638A (ja) 2022-10-12
IL276871A (en) 2020-10-29
IL313368A (en) 2024-08-01
EP3755312A4 (en) 2022-03-16
NI202000056A (es) 2021-01-11
AU2019223187A1 (en) 2020-09-17
JP2021513998A (ja) 2021-06-03
CA3092076A1 (en) 2019-08-29
JP2024075655A (ja) 2024-06-04
KR20240091043A (ko) 2024-06-21
CN112087999A (zh) 2020-12-15
BR112020017179A2 (pt) 2020-12-22
WO2019165379A1 (en) 2019-08-29
ECSP20060179A (es) 2020-12-31
SG11202008056SA (en) 2020-09-29
MA51914A (fr) 2020-12-30
AU2022204521A1 (en) 2022-07-21
AU2022204521B2 (en) 2024-09-05
MX2023009281A (es) 2023-08-17
KR20230075531A (ko) 2023-05-31
AU2024205858A1 (en) 2024-09-05
NZ767378A (en) 2024-03-22
EP3755312A1 (en) 2020-12-30
PE20211752A1 (es) 2021-09-06
MX2020008704A (es) 2020-12-07
MY202993A (en) 2024-05-31

Similar Documents

Publication Publication Date Title
US11660273B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US10695304B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
CN120827545A (zh) 用于对映体富集的或纯的安非他酮的剂型和方法
US11660274B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20190216801A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20190216800A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11179352B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11433035B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US11331285B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US12102606B2 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20200222339A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
US20220249405A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
CN114423417A (zh) 用于对映体富集的或纯的安非他酮的剂型和方法
US20240277635A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK40043597A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination